Swedish Ibrance Registries Insights (SIRI)
ConditionMalignant Neoplasm of Breast
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPfizer
About this trial
The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.
Eligibility criteria
Qualifiers
One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
Age ≥18 years at index date
Disqualifiers
None
Trial design
Treatments tested in this trial
- palbociclib
Treatment groups
1,500 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov